Search

Rare eye diseases: progress continues with authorised orphan medicines and breakthrough technologies

An update on the development of orphan medicines, recent regulatory treatment approvals for rare eye conditions and advances in retinal prosthetic technologies for blinding diseases. The prevalence of a rare disease is based usually on a range of estimates and...

Improving cataract efficiency: insights and learnings from expert practitioners

An evening surgical meeting sponsored by Théa Pharmaceuticals Ltd brought together leading experts to share insights and experience on practice strategies to enhance the efficiency of cataract surgery. Streamlining patient flow to optimise capacity and efficiency Qasim Mansoor, Consultant Ophthalmic...

Pathological myopia: a trainer’s perceptive

High myopia is defined as myopic refraction of greater than -6 dioptres with an axial length greater than 26.5mm, while pathological myopia is myopic refraction with posterior pole degeneration [1]. These degenerative changes can affect a young population and in...

Specialist high-street eye clinics for managing patients with retinal disorders can enhance care standards

The author examines the successful introduction of community-based retinal clinic services by Manchester University NHS Foundation Trust. Dr Sajjad Mahmood, Consultant Ophthalmologist, MREH, shares experience of establishing community-based medical retina clinic services. Sight loss from age-related macular degeneration (AMD), cataract,...

Redefining healthcare through the eyes

The future of healthcare is being shaped by innovation in eyecare and in particular a field known as oculomics. This discipline leverages ocular biomarkers to provide insights into various health conditions, including cardiovascular diseases and psychological or neurological disorders [1]....

Gene therapy for inherited retinal disease: the Manchester Ocular Gene Therapy Group MDT service

The authors describe the process set up in Manchester for the optimum delivery and assessment of a new gene therapy treatment for patients with RPE65 IRD. Inherited retinal dystrophies (IRDs) are the second commonest cause of severe visual impairment in...

Considerations in the management of retinal disorders

Vision research presentations and publications explore practice considerations in the management of AMD and diabetic retinopathy. Over the past two decades in Europe there has been a decreasing prevalence of age-related macular degeneration (AMD) and an improvement in visual acuity...

Optic nerve swelling – your survival guide (part 1)

Assessment of optic nerve appearance and functions is a daily routine in neuro-ophthalmology. Following a recent high profile court case there has been a significant increase in the amount of referral to ophthalmology departments to assess the optic nerve and...

Pegcetacoplan: A breakthrough treatment for dry age-related macular degeneration?

Age-related macular degeneration (AMD) is a degenerative condition affecting the macula, the part of the retina responsible for central vision. It is characterised by the presence of drusen and retinal pigment epithelium (RPE) abnormalities in the absence of other macular...

The International AMD Genomics Consortium study: another success in understanding the complex genetics of AMD

Age-related macular degeneration (AMD) is a neurodegenerative complex disease of the eye and a major cause of blindness and visual impairment among the elderly worldwide. The early stages of the disease are characterised by asymptomatic pigmentary abnormalities and accumulation of...

Update on emerging therapies for age-related macular degeneration

The 23rd European Society of Retina Specialists (EURETINA) Congress, held in Amsterdam, the Netherlands, provided a timely update on anti-complement therapy for geographic atrophy and emerging investigational therapies for neovascular age-related macular degeneration. Anti-complement therapy for geographic atrophy Geographic atrophy...